ESMO 2024 did not bring any practice changing results in the field of lung cancer treatment. Nevertheless, interesting updates from previous trials and early phase trials could impact treatment options in the future.
(BELG J MED ONCOL 2024;18(8):308–310)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
